Clinical Trial Detail

NCT ID NCT02879162
Title Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Canadian Cancer Trials Group
Indications

osteosarcoma

ovarian clear cell carcinoma

anal canal squamous cell carcinoma

salivary gland carcinoma

sarcoma

mucosal melanoma

acral lentiginous melanoma

carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult child senior

Additional content available in CKB BOOST